middle.news
Zelira Secures $3.25M to Advance FDA Trials for HOPE® 1 in Autism-Linked Syndrome
7:03pm on Monday 2nd of June, 2025 AEST
•
Biopharmaceutical
Read Story
Zelira Secures $3.25M to Advance FDA Trials for HOPE® 1 in Autism-Linked Syndrome
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Fourth funding tranche of US$681,000 received from 2011 Forman Trust
Total SPV funding for HOPE® 1 FDA trials now US$3.25 million
Positive FDA feedback on Phase 1 trial design targeting irritability in PMS with ASD
Zelira manages SPV and plans further fundraising rounds
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE